title: Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402.
authors.forename: Savita
authors.initials: S
authors.lastname: Pahwa
authors.forename: Petronella
authors.initials: P
authors.lastname: Muresan
authors.forename: John
authors.initials: J
authors.lastname: Sleasman
authors.forename: Terry
authors.initials: T
authors.lastname: Fenton
authors.forename: John
authors.initials: J
authors.lastname: Moye
authors.forename: Audra
authors.initials: A
authors.lastname: Deveikis
authors.forename: Diane
authors.initials: D
authors.lastname: Wara
authors.forename: Russ
authors.initials: R
authors.lastname: Van Dyke
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002648:Child; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D007166:Immunosuppressive Agents; D007376:Interleukin-2